Catalyst Biosciences : Investor presentation 5.9 MB

CATALYST BIOSCIENCES

Corporate Overview

12 January 2022

Forward looking statements

Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-looking statements. This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, our plans for CB 4332 and the rest of our complement programs, our plans to continue to support Biogen in the development of CB 2782-PEG, the statement that complement has broad potential, can be combined with conventional therapies and will open opportunities in multiple disease settings, as well as statements about the benefits of our protease engineering platform.

Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward- looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that Biogen could terminate our agreement for the development of CB 2782-PEG, that our complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that we may need to raise additional capital, and other risks described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. We do not assume any obligation to update any forward-looking statements, except as required by law.

© Catalyst Biosciences

2

Modulating Biological Systems with Nature's Regulatory Proteins

Proteases are nature's key regulatory proteins

Innovative engineered molecules to degrade or activate therapeutic targets

Applicable across multiple disease areas

We harness the regulatory power of proteases

© Catalyst Biosciences

Catalyst's protease platform in complement

Validated across three programs

CB 2782-PEG	CB 4332 PK extended CFI
Best-in-class profile for dry AMD	Restoring balance to complement
Extended pharmacodynamics	where CFI activity is insufficient

Novel C3-degrader for	Engineered CFI entering
dry AMD	the clinic in 2022

© Catalyst Biosciences

Engineered proteases

Protease platforms tailored to improve C3b & C4b regulation

C4b C3b

ProTUNE™

PLATFORM

C3b/C4b degrader platform delivering candidates in 2022

4

Unique targeted approach to complement regulation

Classical pathway

Lectin pathway

Alternative pathway

	Cascade initiation	Cascade regulation	Terminal complement
	• C4b Degraders	• CB 2782-PEG	• C3a/C5a Degraders
	• C3b Degraders	• CB 4332
			C3a Degrader	Inflammation
			Proinflammatory
				Anaphylatoxins
C1r	C2		C3a
C4b
C1s
C4

	CB 4332 (CFI)	C3		C5
MASP	C4b Degrader	C3b	C5a
	C3b Degrader
							Terminal Pathway
				CB 2782-PEG		C5a Degrader	Membrane attack complex
C3
FB FD	C3b				C5b
(H2O)

© Catalyst Biosciences

5